Commerzbank Aktiengesellschaft FI Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 101.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,261 shares of the company’s stock after purchasing an additional 6,174 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Moderna were worth $483,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the fourth quarter worth approximately $37,000. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after purchasing an additional 388 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $35.21 on Thursday. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock’s 50-day simple moving average is $36.82 and its 200-day simple moving average is $49.78. The firm has a market cap of $13.58 billion, a price-to-earnings ratio of -3.79 and a beta of 1.86.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRNA. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Finally, Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.